Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Efzofitimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
efzofitimod (ATYR-1923) is under development for the treatment of rare pulmonary diseases with an immune component (RPIC) including interstitial lung diseases such as chronic hypersensitivity pneumonitis and connective tissue diseases (CTD-ILD), pulmonary sarcoidosis, systemic sclerosis related interstitial lung disease (SSc-ILD), rheumatoid arthritis and coronavirus disease 2019 (COVID-19) with severe pneumonia. It is administered by intravenous route. The drug candidate targets neuropilin-2. It is being developed based on tRNA synthetase platform. The drug candidate constitutes an immunoglobin Fc fused with the immuno-modulatory domain (iMod domain) of histidine aminoacyl tRNA synthetase (HARS).
ATyr Pharma overview
aTyr Pharma is a clinical-stage biotechnology company. It includes in discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company’s ATYR1923 is a clinical-stage product candidate based on the resokine pathway which binds to the neuropilin-2 receptor harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of the extracellular functionality of tRNA synthetases. aTyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases and metabolic disorders. The company collaborates with research institutions for its research and development activities. aTyr Pharma is headquartered in San Diego, California, the US.
For a complete picture of Efzofitimod’s drug-specific PTSR and LoA scores, buy the report here.